ArticleJournal of advanced research2026
Peptide IRW upregulates ACE2 in spontaneously hypertensive rats via dopamine/D1R signaling pathway.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of cardiovascular-kidney-metabolic syndrome with blinding eye diseases: insights from a UK Biobank cohort analysis.Eye (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe bioactive peptide IRW lowers blood pressure in spontaneously hypertensive rats (SHRs) by upregulating angiotensin-converting enzyme 2 (ACE2), but the underlying mechanisms remain unclear.
objectivesThis study aimed to elucidate the mechanisms underlying IRW-mediated ACE2 upregulation through integrated transcriptomic and metabolomic analyses.
methodsMesenteric arteries from IRW-treated SHRs underwent transcriptomic and metabolomic analyses. Weighted gene co-expression network analysis (WGCNA) and transcription factor prediction were performed to identify ACE2-associated regulators. Subsequent validation was conducted both in vitro with EA.hy926 endothelial cells and in vivo via receptor blocker infusion in SHRs.
resultsWGCNA of transcriptomic data identified 651 genes co-expressed with ACE2, including 17 predicted transcription factors, notably nuclear receptor 4A1 (Nr4a1). Metabolomic analysis revealed a significant increase in dopamine after IRW treatment, and its abundance correlated with ACE2 expression. Ingenuity pathway analysis indicated that dopamine may activate Nr4a1 via the dopamine D1 receptor (D1R). In vitro, dopamine (1 μM) upregulated protein levels of ACE2 and Nr4a1, effects blocked by the D1R antagonist SCH23390 (10 μM). Additionally, Nr4a1 knockdown reduced dopamine-induced ACE2 upregulation. In SHRs, D1R blockade abolished IRW's antihypertensive effects and ACE2 upregulation.
conclusionIRW-driven ACE2 upregulation in vivo relies on the dopamine/D1R signaling pathway, highlighting the therapeutic potential of this pathway for ACE2-related conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.